

The Impact of Obesity on the Host–Pathogen Interaction with Influenza Viruses – Novel Insights: Narrative Review

Victor Daniel Miron^{1,2}, Anca Cristina Drăgănescu^{1,2}, Daniela Pițigoi^{1,2}, Victoria Aramă^{1,2}, Adrian Streinu-Cercel^{1,2,*}, Oana Săndulescu^{1,2,*}

¹Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania; ²National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, Bucharest, Romania

*These authors contributed equally to this work

Correspondence: Anca Cristina Drăgănescu, Department of Pediatrics, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, National Institute for Infectious Diseases “Prof. Dr. Matei Balș”, No. 1 Dr. Calistrat Grozovici Street, Bucharest, 021105, Romania, Email anca.draganescu@umfcd.ro

Abstract: After exposure to a viral pathogen, the host–pathogen interaction is essential to determine whether or not infection will ensue, and what the clinical outline of the infection will be. Recent research has shown that the patient with obesity presents a set of particular pathophysiological changes that lead to higher severity of viral infections, and this is particularly true for infection with influenza viruses. Herein, we describe the main metabolic, endocrine, and immune dysregulations that occur in the presence of obesity and their impact on driving intra-host viral diversity, leading to heightened severity and virulence of influenza. We show that obesity is linked to modified responses of both the innate and adaptive immune systems during viral infections, including influenza. Due to chronic inflammation and metabolic, endocrine, and signaling pathway disruptions, individuals with obesity have a suboptimal immune response. This results in longer illness duration, increased virus shedding, higher risk of hospitalization and complications, and greater mortality rates. Additionally, they may have a blunted response to vaccination and a higher likelihood of genetic mutation selection. Understanding the intricate interplay between obesity and viral pathogenesis is crucial for developing efficacious therapeutic approaches and public health policies, particularly in light of the escalating worldwide incidence of obesity.

Keywords: influenza, obesity, severity, metabolic syndrome, inflammation

Introduction

After exposure to a viral pathogen, the host–pathogen interaction is essential to determine whether or not infection will ensue, and what the clinical outline of the infection will be. In many instances, in immunocompetent hosts, exposure to a respiratory virus leads to self-limiting non-severe disease. However, certain host-specific factors can alter the host–pathogen interaction and facilitate more severe disease. Recent research has shown that the patient with obesity presents a set of particular pathophysiological changes that lead to higher severity of viral infections, and this is particularly true for infection with influenza viruses.

According to the World Health Organization (WHO), it is estimated that, in 2016, 39% of adults worldwide were overweight and 13% were obese.¹ A recent study from Spain shows an even higher prevalence in 2020, 55.8% for overweight status, and 18.7% for obesity in adults.² The data is also worrying in children, where up to 17% of those aged between 2 and 19 years are obese,³ while in Romania, the prevalence of overweight children was reported at 7.5% and that of obese children at 18.5% in 2018.⁴

With the high worldwide prevalence of obesity, it has become essential to understand the main metabolic, endocrine, and immune dysregulations that occur during infection with influenza virus, as well as their impact on driving intra-host viral diversity, leading to heightened clinical severity and increased viral virulence.

Influenza Infection in Humans: Clinical Expression and Impact of Obesity

The human host's response to influenza virus infection is not always effective and depends on factors such as age, comorbidities, genetic traits, and immune memory from previous exposure to antigens through vaccination or infection. This creates a complex and dynamic interaction between the host and influenza viruses, where host-specific factors play a crucial role. Increased susceptibility to infection, more severe forms of the disease, or both, can be seen in particular patient groups. As a result, specific risk groups for influenza have been identified by international consensus, for whom priority vaccination is recommended.

According to the European Centre for Disease Prevention and Control (ECDC), the groups at risk for severe influenza are older adults (aged 65 years and older) and all persons with comorbidities. These comorbidities include cardiovascular disease, chronic lung disease, diabetes, chronic liver disease, chronic kidney disease, neurological or neuromuscular pathology, obesity, physical disability, and immunosuppression.⁵ The WHO also identifies pregnant women and those in the first two weeks postpartum, children under 59 months of age, and adolescents under 19 years of age on chronic salicylate therapy as risk groups.⁶ The US Centre for Disease Prevention and Control (CDC) further includes patients with hematological conditions (eg, thalassemia), metabolic conditions (eg, genetic metabolic disease and mitochondrial disease), and patients with a history of stroke as additional risk groups for influenza complications.⁷

Obesity has been identified as a common comorbidity among patients hospitalized for influenza, with a prevalence ranging from 4.2% to 8.7%, following cardiovascular disease and diabetes.^{8,9} This is often compounded by the coexistence of these conditions in the same patient, leading to an unfavorable outcome. Furthermore, obesity rates of up to 6.8% have been identified in the pediatric population hospitalized with influenza,⁹ including young children under 5 years of age.

Influenza typically presents with systemic symptoms such as fever, malaise, headache, myalgia, fatigue, and respiratory symptoms such as cough, sore throat, and nasal congestion.¹⁰ Fever is the predominant symptom in up to 90% of elderly patients and 97–99% of children^{9,11} with a duration of approximately 5 days. Obese individuals also commonly experience fever during influenza, and the duration of the fever is significantly longer.¹² Although other symptoms have not been identified with significantly different frequencies compared to the non-obese population,¹² dyspnea has been reported more frequently in obese individuals. This is a sign of lower respiratory tract impairment and is associated with a higher risk of pneumonia.¹³

First Observations Regarding the Association Between Obesity and Severity of Influenza; Current Relevance

Obesity was first recognized as a specific risk factor for severity in the 2009 influenza A/H1N1 pandemic, when it was noticed that morbid obesity, defined as a body mass index (BMI) ≥ 40 was associated with a 2.8-fold increased risk of death from influenza and a BMI ≥ 45 with a 4.2-fold increased risk of death.¹⁴ Subsequently, the broader association, beyond pandemic influenza, between obesity and seasonal influenza was also described, confirmed, and reconfirmed.

One of the important studies that confirmed this association between obesity and the risk of severe respiratory tract infections was that conducted in Canada by Kwong et al; they analysed adult patients, aged 18–64 years, in a cohort study that included 12 consecutive influenza seasons from 1996/97 to 2007/08. The study included 82,545 patients, totaling 105,035.6 person-years over the influenza seasons studied, and its main results indicated with a high degree of certainty that patients with obesity had a higher risk of severe forms of respiratory infections requiring hospitalization, as follows: class I obesity (BMI=30–34.9) 1.45-fold higher risk, class II or III obesity (BMI ≥ 35) 2.12-fold higher risk. Importantly, class II or III obesity retain their predictive value for severe respiratory disease even in patients with no other known risk factors, with a 5.10-fold increased risk.¹⁵

While the study referenced above had looked at medically attended respiratory illness, a recent meta-analysis included 35 papers that studied specifically only patients with confirmed influenza virus infection. It reconfirmed the role of obesity as a major risk factor for acquiring influenza (1.29-fold higher risk), for requiring hospitalization for influenza (1.62-fold higher risk) as well as for severe forms of influenza (1.56-fold higher risk) and for death from influenza (1.99-fold higher risk), respectively.¹⁶

Furthermore, a recent Mendelian randomization study has demonstrated that obesity is associated with an increased risk of acute or chronic respiratory diseases. Specifically, the study found that obesity is associated with an increased risk

of influenza (OR = 1.243), ranking third among acute diseases after acute unspecified lower respiratory infection (OR = 1.303) and acute bronchitis (OR = 1.252).¹⁷

The COVID-19 pandemic has posed important challenges,^{18,19} and it has also highlighted the importance of studying obesity as a risk factor for respiratory disease. As with influenza, research has shown a strong correlation between obesity and the severity of SARS-CoV-2 infection. Therefore, the presence of obesity was found to be correlated with the severity, duration of hospitalization, progression to respiratory failure, admission to intensive care, need for mechanical ventilation, and COVID-19 mortality, with a direct correlation to the BMI value.^{20–22} Additionally, the COVID-19 pandemic has resulted in increased rates of obesity in the general population.^{23,24} Therefore, given the rising rates of obesity and the renewed circulation of influenza viruses at levels comparable to pre-pandemic times,²⁵ it is crucial to comprehend how the clinical picture of influenza is affected in overweight patients. Clinicians must be mindful of the important risks that influenza associates in patients with obesity and take timely measures for risk mitigation. Establishing effective management requires a thorough understanding of the underlying pathophysiological mechanisms.

Dysregulations Specific to the Obese Host Alter Its Interaction with Influenza Viruses and Drive Clinical Severity and Viral Virulence

The observed associations mentioned above between obesity and heightened severity of influenza are explained by a set of highly complex pathophysiological mechanisms that derive from a set of important metabolic, endocrine, and immune changes specific to the patient with obesity, which we aim to describe below, in the light of the latest published data.

Metabolic Dysregulation

The most well-studied obesity-induced dysregulations occur in the metabolic system, with a clear association between obesity and insulin resistance, glucose intolerance that can progress to diabetes mellitus, dyslipidemia, and cardiovascular disease, all culminating in metabolic syndrome.²⁶ Conversely, patients with diabetes mellitus have two-fold higher odds of associating obesity, and are particularly affected by influenza.²⁷ Obesity in itself induces a number of important changes at the metabolome level; these include alterations in the N-acyltransferase pathway and in a set of fatty acid and nucleotide pathways, which are expressed by increases in the following metabolites in the lung: P-cresol sulphate, glutamyl-proline, tetrahydrocortisol, 3-hydroxybutyric acid, and multiple species of acyl-carnitine.²⁸

Increased free fatty acid levels are part of the main changes associated with obesity, studied in large cohorts of patients, where a 26% increase compared to a non-obese population was reported, and this is considered to be one of the determinants of insulin resistance.²⁹

This particularity of the obese host influences the interaction with influenza viruses directly, viral replication being amplified in the presence of increased lipid content in fatty acids,³⁰ but also indirectly, through the role of fatty acids as signaling molecules for immune cells.³¹

Almond M. et al conducted a study on the correlation between dysregulated cholesterol levels and increased leptin concentrations in both upper and lower airways of obese individuals. The study found a negative correlation between leptin concentrations and the induction of interferon (IFN) synthesis, regardless of influenza virus subtype. Additionally, the study found a positive correlation between leptin values and bronchial adenosine monophosphate (AMP) levels. Therefore, it seems that the disturbance of fatty acid metabolism leads to the dysregulation of antiviral immunity in the respiratory tract.³²

In overweight individuals, levels of essential fatty acids, including long-chain saturated fatty acids and ω -6 polyunsaturated fatty acids, are affected.^{33,34} Arachidonic acid (AA) is one of the most important of these fatty acids, and it has been shown to play a role in the pro-inflammatory response during viral infections.³⁵ Chandrasekaran R. et al conducted a study on obese mice and found that elevated lung levels of AA induced a strong cytokine response in human bronchial epithelial cells when exposed to influenza A viruses. Furthermore, obesity in these mice resulted in increased activation of the AA-p38 mitogen-activated protein kinases (MAPK) pathway after infection with influenza A viruses. Suppression of this pathway decreased inflammation, lesions, and improved survival rates.³⁶ Particularly, the p38 MAPK is essential for generating inflammatory cytokines, as well as for the replication of viruses.³⁷

Another important issue that arises as a result of metabolic dysregulation in obese patients is the impaired resolution of inflammation.³⁸ Normally, during the quenching of the inflammatory process, there is a shift in lipid classes, characterized by a reduction in the production of AA-derived mediators, along with a simultaneous increase in compounds known as specialized proresolving mediators (SPMs) also derived from essential fatty acids.³⁹ The deficiency of SPM, which was identified in obese mice, leads to prolonged viral replication and an inflammatory process.^{40,41}

Endocrine Dysregulation

Obesity also dysregulates the endocrine system on multiple levels. For example, part of a wider meta-inflammatory status specific for obese patients, chronic inflammation of the pituitary gland has been reported.⁴² This is one of the main endocrine glands that also plays a role in modulating the immune response to infection, mainly by regulating lymphocyte differentiation processes.⁴³ Growth hormones and prolactin are essential for lymphocyte maturation, for ensuring the ability of lymphocytes to respond to antigen presence, and for maintaining the immunocompetence status.⁴³

Other endocrine glands that are affected in obesity are the thyroid and adrenals. The association between thyroid damage and obesity is bidirectional. On the one hand, hypothyroidism stimulates weight gain, but the reverse has also been described, namely the induction by obesity of a degree of secondary hypothyroidism, with a decreased level of free thyroxine (fT4) and an increased level of thyroid stimulating hormone (TSH), as well as a degree of autoimmunity at the thyroid level, mainly determined by leptin produced by excessive numbers of adipocytes.⁴⁴ Thyroid hormones are important regulators of lymphocyte signaling at the nuclear level as they control nuclear transcription factors; TSH also plays a direct stimulatory role in immunoglobulin secretion and interleukin (IL)-2 production,⁴³ and hypothyroidism has been described to be associated with the induction of a degree of immunosuppression.⁴⁵

Glucocorticoid metabolism is also altered in obesity, with lower cortisol levels in the liver but higher in adipose tissue.⁴⁶ Glucocorticoids are considered immunosuppressive hormones, and play an important role in cytokine production,⁴³ which is why altered glucocorticoid levels in the presence of obesity may affect the regulation of immune processes.

Another important aspect to discuss is related to the negative impact of obesity on serum testosterone levels.^{47,48} Similarly, hypotestosteronemia leads to increased adipose tissue mass. Thus, a vicious circle is created, in which the two imbalances mutually maintain each other.^{47,48} Low testosterone levels have been associated with a poor immune response to influenza infection. Studies in murine models have shown that testosterone supplementation in females⁴⁹ or elderly males⁵⁰ can protect against severe influenza by modulating the pro-inflammatory response in their lungs.

At the same time, it is known that white adipose tissue has an intense endocrine activity and secretes numerous hormones and metabolites.⁴⁶ Thus, in adipose tissues collected from murine models infected with influenza virus, elevated levels of proinflammatory cytokines have been identified, as well as elevated levels of leptin.⁵¹ In addition to what has been previously discussed about leptin, it is known to play an essential role in regulating the interaction between energy metabolism and the immune system, due to the presence of its receptor throughout the immune system.⁵² Also, the contribution of pre-existing high levels of leptin to the development of severe lung injury has been documented in mouse studies.⁵³

Overall, there is a co-influencing, looping relationship between overweight and endocrine disruption that alters metabolic and immune responses, with major impact during acute infections such as influenza.

Meta-Inflammation and Immune Dysregulation

Ample studies in murine obesity models have identified a degree of persistent inflammation associated with obesity. For example, in the adipose tissue, an increased influx of immune cells has been described, predominantly for monocytes, granulocytes such as neutrophils, mast cells, basophils, but also for CD4 T helper-1 lymphocytes, CD8 lymphocytes, and natural killer cells, in parallel with decreased levels of eosinophils, regulatory T lymphocytes, and T helper-2 lymphocytes.⁵⁴ In addition, CD4 and CD8 T cells express reduced numbers of CD69, CD28, CD40 ligands and decreased production of IFN- γ and granzyme B, suggesting deficiencies in T cell activation and function.⁵⁵ In parallel, levels of pro-inflammatory cytokines such as tumor necrosis factor (TNF) α and IL-1 β , levels of non-esterified free fatty acids and acylcarnitines are increased,⁵⁴ and so is the release of reactive oxygen species from adipose tissue.^{54,56}

This pro-inflammatory status is also found in the respiratory tract of the obese host. Murine obesity models have shown that influenza virus infection leads to a marked cellular infiltrate in the lung, initially monocytic in the first days

after infection, and subsequently neutrophilic,⁵⁷ but with lower levels of macrophages and regulatory T cells.^{28,54} These changes have been attributed to increased lung levels of granulocyte colony-stimulating factor (G-CSF), CXCL10, CXCL1, and monocyte chemoattractant protein-1 (MCP-1), as well as IL-6, which is known to play a pro-inflammatory role.⁵⁷ In parallel, decreases have been reported in transforming growth factor (TGF)- β ,⁵⁷ which normally plays a key role in modulating the pro- and anti-inflammatory response,⁵⁸ as well as in the levels of IFN- γ ,⁵⁷ which is involved in the innate and the adaptive immune response to infection, but which also plays a complex role in modulating inflammatory status.⁵⁹ These changes occurring during the pathogenesis of influenza infection are associated with increased permeability of the alveolar-capillary barrier and with a longer persistence, above 14 days, of the inflammatory process in the lungs, compared to non-obese murine models, in parallel with a marked decrease in epithelial regeneration.⁵⁷

This high degree of immunopathological damage is also associated with high influenza mortality in murine models of obesity^{56,57} – Figure 1. Importantly, all these changes have been described for both genetically induced obesity and diet-induced obesity, but this increased severity of lung damage in the presence of obesity can be prevented by early administration of antiviral treatment, and the role of high-dose oseltamivir in preventing severe forms of influenza has been studied.⁵⁷




Figure 1 Pathogenesis of influenza virus infection in obese hosts-specific dysregulations in adipocytes, lungs and in the overall pathogen–host interaction (figure created with BioRender.com).

Abbreviations: Mo, monocytes; Ne, neutrophils; Mf, macrophages; Ba, basophils; Th, T helper; NK, natural killer cells; TNF α , tumor necrosis factor α ; IL, interleukin; FFA, free fatty acids; ROS, reactive oxygen species; Treg, regulatory T cells; G-CSF, granulocyte colony-stimulating factor; MCP-1, monocyte chemoattractant protein-1; TGF- β – transforming growth factor β ; IFN, interferon.

The Obese Host Provides an Environment Conducive for the Selection of Virulent Influenza Strains

Patients with obesity and symptomatic influenza A have a 42% longer duration of influenza A virus shedding compared to patients without obesity, whereas patients with obesity and paucisymptomatic or asymptomatic influenza A virus infection have a 104% longer duration of virus shedding.⁶⁰ This phenomenon indicates, on the one hand, a higher contagiousness of obese patients with influenza, and, on the other hand, creates the prerequisites for viral mutation selection through prolonged viral replication under conditions of low immune pressure.

To ascertain this phenomenon, Honce et al recently studied influenza A/California/04/2009 infection in murine obesity models, and found that as soon as 3 days post-infection, intra-host viral diversity was increased in the lungs in the obese host, and selection of virulence-associated mutations was favored.⁶¹ Moreover, Honce et al reported that serial inoculation of influenza virus isolated from obese murine models selected influenza virus strains with higher replication as well as higher pathogenicity, expressed by higher clinical severity starting with the third viral passage, as well as higher virulence expressed by higher mortality coupled with a lower mean lethal dose 50%, phenomena that did not occur in non-obese hosts⁶¹ (Figure 1). They further went on to study the main mechanism that allows selection of these influenza virus strains with increased pathogenicity and virulence, and they found a decrease in type I IFN signaling, with decreased expression of genes responsible for induction and signaling through the IFN pathway, a phenomenon that occurs within the first 8 hours following influenza virus infection.⁶¹ To confirm the relevance of these observed phenomena in murine models to the human host, Honce et al also confirmed these experiments *in vitro* on human bronchial epithelium from obese donors.⁶¹ Other recent research on avian variants of the influenza virus (H9N2) has identified increased positive selection on *de novo* mutations in obese murine subjects, resulting in a variety of non-synonymous changes.⁶²

The analysis of the efficacy of antiviral treatment revealed that the use of oseltamivir did not positively impact virus clearance in obese mice, and no resistance mutations were identified. However, it led to phenotypic resistance *in vitro*.⁶³ This suggests the need for careful surveillance of pharmaceutical interventions in obese patients with influenza, as well as monitoring for possible resistance mutations in the neuraminidase gene.

These findings are crucial in clinical practice and epidemiological surveillance of influenza viruses. It is necessary to establish correct management rapidly and limit human-to-human transmission in hosts with obesity to prevent the accumulation of influenza virus mutations.

Suboptimal Coverage of Influenza Vaccination Among Obese Patients

Vaccination is the main instrument available for preventing influenza; however, its yearly uptake is in most countries less than optimal. Patients with comorbidities are among the most important at-risk categories and are prioritized for influenza vaccination, according to the most important regulatory authorities, including the WHO and the ECDC. While obesity in itself does represent a comorbidity, recent studies have shown that in most cases it is not perceived as such and that influenza vaccination uptake is 71% lower among patients with obesity, compared with other risk categories,⁶⁴ and 24% lower compared to that of non-obese patients.⁶⁵ A study conducted in Spain found that obese adults had a lower rate of influenza vaccination compared to adults with other comorbidities. When vaccinated, they were more likely to have other chronic conditions, particularly diabetes, cardiovascular disease, or chronic lung disease.⁶² Similarly, among the pediatric population, Karachaliou et al recently demonstrated that obese children had significantly lower rates of influenza vaccination compared to the general pediatric population; by the age of 4, only 13.3% of obese children were vaccinated compared to 37% of the general population, and by the age of 10, only 2.9% of obese children were vaccinated compared to 40% of the general population.⁶⁶ For these reasons, it is important to study the determinants of vaccine uptake for each specific risk group, in order to better address each gap in vaccination coverage with a targeted and tailored approach.^{67–69}

Inadequate Response to Influenza Vaccination in the Obese Host

Inadequate response to 2009 A/H1N1 vaccination has been described in murine obesity models, with lower levels of vaccine-generated antibodies, lower neutralizing activity,⁷⁰ as well as lower levels of influenza virus-specific memory CD8 T lymphocytes.⁷¹ This inadequate response is at least partly explained by the obesity-induced chronic pro-

inflammatory status, expressed by elevated serum and adipocyte MCP-1 levels, and has been associated with a more severe pathogenesis of pulmonary inflammatory damage following influenza exposure in the presence of obesity, even after vaccination.⁷¹ Obesity has recently been shown to induce B-cell dysfunction similar to that seen in the aging process, thus post-vaccination-induced hemagglutinin-specific inhibitory antibody titers were reduced in overweight individuals, while proinflammatory cytokine and autoimmune antibody levels were elevated.⁷² Additionally, Neidich et al showed that although some adults with obesity may have an effective response to vaccination, they are twice as likely to develop influenza compared to non-obese adults.⁷³ Among children, the presence of adiposity does not appear to significantly alter the specific antibody response, and vaccine efficacy is similar to that among children of normal weight for age.^{74,75}

Conclusion

In conclusion, there are multiple pathophysiological mechanisms that occur in the obese host and that alter their interaction with influenza viruses, leading to more severe infection and to the selection of more virulent viral variants. These can include altered immune responses, such as changes in the activity and effectiveness of various immune cells, and may contribute to a higher risk of complications and prolonged illness. A good understanding of these mechanisms is important in order to better guide timely treatment intervention and to potentially develop tailored approaches to the management of influenza in the obese patient.

Disclosure

The authors report no conflicts of interest in this work.

References

1. World Health Organization. Obesity and overweight 2021. Available from: <https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight>. Accessed August 8, 2023.
2. Gutierrez-Gonzalez E, Garcia-Solano M, Pastor-Barriuso R, et al. Socio-geographical disparities of obesity and excess weight in adults in Spain: insights from the ENE-COVID study. *Front Public Health*. 2023;11:1195249. doi:10.3389/fpubh.2023.1195249
3. Brady TM. Obesity-Related Hypertension in Children. *Front Pediatr*. 2017;5:197. doi:10.3389/fped.2017.00197
4. Miron VD, Bar G, Filimon C, Gaidamut VA, Craiu M. Monitoring of excess body weight in children in the emergency department of a tertiary pediatric hospital in Bucharest, Romania. *Maedica*. 2021;16(3):389–393. doi:10.26574/maedica.2021.16.3.389
5. European Centre for Disease Prevention and Control. Risk groups for severe influenza 2023. Available from: <https://www.ecdc.europa.eu/en/seasonal-influenza/prevention-and-control/vaccines/risk-groups>. Accessed August 10, 2023.
6. World Health Organization. Vaccines against influenza: WHO position paper, May 2022. *Weekly Epidemiological Rec*. 2022;19:185–208.
7. Centers for Disease Control and Prevention. People at Higher Risk of Flu Complications 2023. Available from: <https://www.cdc.gov/flu/highrisk/index.htm>. Accessed August 10, 2023.
8. Miron VD, Banica L, Sandulescu O, et al. Clinical and molecular epidemiology of influenza viruses from Romanian patients hospitalized during the 2019/20 season. *PLoS One*. 2021;16(11):e0258798. doi:10.1371/journal.pone.0258798
9. Andrew MK, Pott H, Staadegaard L, et al. Age differences in comorbidities, presenting symptoms, and outcomes of influenza illness requiring hospitalization: a worldwide perspective from the global influenza hospital surveillance network. *Open Forum Infect Dis*. 2023;10(6):ofad244. doi:10.1093/ofid/ofad244
10. Sandulescu O, Draganescu A, Pitigoi D. Influenza redefined - clinical and epidemiological insight. *Germes*. 2019;9(2):60. doi:10.18683/germes.2019.1158
11. Cohen LE, Hansen CL, Andrew MK, et al. Predictors of severity of influenza-related hospitalizations: results from the Global Influenza Hospital Surveillance Network (GIHSN). *J Infect Dis*. 2023. doi:10.1093/infdis/jiad303
12. Deng Q-Z, Hu A-R, Li H-S. Clinical analysis of 42 obese patients with 2009 pandemic influenza A (H1N1). *Dis Surveil*. 2010;25(9):713–715.
13. Schreter I, Kristian P, Tkacova R. Obesity and risk of pneumonia in patients with influenza. *Eur Respir J*. 2011;37(5):1298; author reply 9–300. doi:10.1183/09031936.00188610
14. Louie JK, Acosta M, Samuel MC, et al. A novel risk factor for a novel virus: obesity and 2009 pandemic influenza A (H1N1). *Clin Infect Dis*. 2011;52(3):301–312. doi:10.1093/cid/ciq152
15. Kwong JC, Campitelli MA, Rosella LC. Obesity and respiratory hospitalizations during influenza seasons in Ontario, Canada: a cohort study. *Clin Infect Dis*. 2011;53(5):413–421. doi:10.1093/cid/cir442
16. Zhao X, Gang X, He G, et al. Obesity increases the severity and mortality of influenza and COVID-19: a systematic review and meta-analysis. *Front Endocrinol*. 2020;11:595109. doi:10.3389/fendo.2020.595109
17. Yang W, Yang Y, Guo Y, Guo J, Ma M, Han B. Obesity and risk for respiratory diseases: a Mendelian randomization study. *Front Endocrinol*. 2023;14:1197730. doi:10.3389/fendo.2023.1197730
18. Tarzjani SD, Kamalzadeh S, Moghadam MT, Ashoobi MT. Clinical challenge of co-infection of SARS-CoV-2 with influenza during the influenza circulation season: suggestions for prevention. *Germes*. 2023;13(2):188–191. doi:10.18683/germes.2023.1384
19. Radu F, Mates I, Gheorghita V. Bucharest mobile military hospital-response to the COVID-19 pandemic. *Roman J Mil Med*. 2020;123(2):141–147.

20. Arulanandam B, Beladi H, Chakrabarti A. Obesity and COVID-19 mortality are correlated. *Sci Rep.* **2023**;13(1):5895. doi:10.1038/s41598-023-33093-3
21. Onyango TB, Zhou F, Bredholt G, et al. SARS-CoV-2 specific immune responses in overweight and obese COVID-19 patients. *Front Immunol.* **2023**;14:1287388. doi:10.3389/fimmu.2023.1287388
22. Singh R, Rathore SS, Khan H, et al. Association of obesity with COVID-19 severity and mortality: an updated systemic review, meta-analysis, and meta-regression. *Front Endocrinol.* **2022**;13:780872. doi:10.3389/fendo.2022.780872
23. Nour TY, Altintas KH. Effect of the COVID-19 pandemic on obesity and its risk factors: a systematic review. *BMC Public Health.* **2023**;23(1):1018. doi:10.1186/s12889-023-15833-2
24. Anderson LN, Yoshida-Montezuma Y, Dewart N, et al. Obesity and weight change during the COVID-19 pandemic in children and adults: a systematic review and meta-analysis. *Obes Rev.* **2023**;24(5):e13550. doi:10.1111/obr.13550
25. Săndulescu M, Săndulescu O. Changing clinical patterns and ear-nose-throat complications of seasonal viral respiratory tract infections. *GERMS.* **2023**;13(4):311–313.
26. Singla P, Bardoloi A, Parkash AA. Metabolic effects of obesity: a review. *World J Diabetes.* **2010**;1(3):76–88. doi:10.4239/wjd.v1.i3.76
27. Pitigoi D, Nătescu M, Streinu-Cercel A, et al. Characteristics of influenza in elderly patients with and without diabetes, hospitalized for severe acute respiratory infection in a tertiary care hospital from Bucharest Romania - a three-year prospective epidemiological surveillance study. *Germs.* **2019**;9(3):142–147. doi:10.18683/germs.2019.1169
28. Milner JJ, Rebeles J, Dhungana S, et al. Obesity increases mortality and modulates the lung metabolome during pandemic H1N1 influenza virus infection in mice. *J Immunol.* **2015**;194(10):4846–4859. doi:10.4049/jimmunol.1402295
29. Arner P, Ryden M. Fatty acids, obesity and insulin resistance. *Obes Facts.* **2015**;8(2):147–155. doi:10.1159/000381224
30. Limsuwat N, Boonarkart C, Phakaratsakul S, Suptawiwat O, Auewarakul P. Influence of cellular lipid content on influenza A virus replication. *Arch Virol.* **2020**;165(5):1151–1161. doi:10.1007/s00705-020-04596-5
31. Hidalgo MA, Carretta MD, Burgos RA. Long chain fatty acids as modulators of immune cells function: contribution of FFA1 and FFA4 receptors. *Front Physiol.* **2021**;12:668330. doi:10.3389/fphys.2021.668330
32. Almond M, Farne HA, Jackson MM, et al. Obesity dysregulates the pulmonary antiviral immune response. *Nat Commun.* **2023**;14(1):6607. doi:10.1038/s41467-023-42432-x
33. Wrzosek M, Zawadzka Z, Sawicka A, Bobrowska-Korczak B, Bialek A. Impact of fatty acids on obesity-associated diseases and radical weight reduction. *Obes Surg.* **2022**;32(2):428–440. doi:10.1007/s11695-021-05789-w
34. Hammad SS, Jones PJ. Dietary fatty acid composition modulates obesity and interacts with obesity-related genes. *Lipids.* **2017**;52(10):803–822. doi:10.1007/s11745-017-4291-9
35. Chandrasekharan JA, Marginean A, Sharma-Walia N. An insight into the role of arachidonic acid derived lipid mediators in virus associated pathogenesis and malignancies. *Prostaglandins Other Lipid Mediat.* **2016**;126:46–54. doi:10.1016/j.prostaglandins.2016.07.009
36. Chandrasekharan R, Morris CR, Butzirus IM, et al. Obesity exacerbates influenza-induced respiratory disease via the arachidonic acid-p38 MAPK pathway. *Front Pharmacol.* **2023**;14:1248873. doi:10.3389/fphar.2023.1248873
37. Yu J, Sun X, Goie JYG, Zhang Y. Regulation of host immune responses against influenza A virus infection by mitogen-activated protein kinases (MAPKs). *Microorganisms.* **2020**;8(7):1067. doi:10.3390/microorganisms8071067
38. Ellulu MS, Patimah I, Khaza'i H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. *Arch Med Sci.* **2017**;13(4):851–863. doi:10.5114/aoms.2016.58928
39. Serhan CN. Pro-resolving lipid mediators are leads for resolution physiology. *Nature.* **2014**;510(7503):92–101. doi:10.1038/nature13479
40. Pal A, Gowdy KM, Oestreich KJ, Beck M, Shaikh SR. Obesity-driven deficiencies of specialized pro-resolving mediators may drive adverse outcomes during SARS-CoV-2 infection. *Front Immunol.* **2020**;11:1997. doi:10.3389/fimmu.2020.01997
41. Pascoal LB, Bombassaro B, Ramalho AF, et al. Resolvin RvD2 reduces hypothalamic inflammation and rescues mice from diet-induced obesity. *J Neuroinflammation.* **2017**;14(1):5. doi:10.1186/s12974-016-0777-2
42. Puliani G, Sbardella E, Cozzolino A, et al. Pituitary T1 signal intensity at magnetic resonance imaging is reduced in patients with obesity: results from the CHIASM study. *Int J Obes.* **2023**;1:4.
43. Berczi I. Pituitary hormones and immune function. *Acta Paediatr Suppl.* **1997**;423:70–75. doi:10.1111/j.1651-2227.1997.tb18376.x
44. Sanyal D, Raychaudhuri M. Hypothyroidism and obesity: an intriguing link. *Indian J Endocrinol Metab.* **2016**;20(4):554–557. doi:10.4103/2230-8210.183454
45. Valli E, Dalotto-Moreno T, Sterle HA, et al. Hypothyroidism-associated immunosuppression involves induction of galectin-1-producing regulatory T cells. *FASEB J.* **2023**;37(4):e22865. doi:10.1096/fj.202200884R
46. Akalestou E, Genser L, Rutter GA. Glucocorticoid metabolism in obesity and following weight loss. *Front Endocrinol.* **2020**;11:59. doi:10.3389/fendo.2020.00059
47. Fui MN, Dupuis P, Grossmann M. Lowered testosterone in male obesity: mechanisms, morbidity and management. *Asian J Androl.* **2014**;16(2):223–231. doi:10.4103/1008-682X.122365
48. Kelly DM, Jones TH. Testosterone and obesity. *Obes Rev.* **2015**;16(7):581–606. doi:10.1111/obr.12282
49. Tuku B, Stanelle-Bertram S, Sellau J, et al. Testosterone protects against severe influenza by reducing the pro-inflammatory cytokine response in the murine lung. *Front Immunol.* **2020**;11:697. doi:10.3389/fimmu.2020.00697
50. Vom Steeg LG, Vermillion MS, Hall OJ, et al. Age and testosterone mediate influenza pathogenesis in male mice. *Am J Physiol Lung Cell Mol Physiol.* **2016**;311(6):L1234–L1244. doi:10.1152/ajplung.00352.2016
51. Ayari A, Rosa-Calatrava M, Lancel S, et al. Influenza infection rewires energy metabolism and induces browning features in adipose cells and tissues. *Commun Biol.* **2020**;3(1):237. doi:10.1038/s42003-020-0965-6
52. Guglielmi V, Colangeli L, D'Adamo M, Sbraccia P. Susceptibility and severity of viral infections in obesity: lessons from influenza to COVID-19. Does leptin play a role? *Int J Mol Sci.* **2021**;22(6):3183. doi:10.3390/ijms22063183
53. Zhang AJ, To KK, Li C, et al. Leptin mediates the pathogenesis of severe 2009 pandemic influenza A(H1N1) infection associated with cytokine dysregulation in mice with diet-induced obesity. *J Infect Dis.* **2013**;207(8):1270–1280. doi:10.1093/infdis/jit031
54. Johnson AR, Milner JJ, Makowski L. The inflammation highway: metabolism accelerates inflammatory traffic in obesity. *Immunol Rev.* **2012**;249(1):218–238. doi:10.1111/j.1600-065X.2012.01151.x

55. Paich HA, Sheridan PA, Handy J, et al. Overweight and obese adult humans have a defective cellular immune response to pandemic H1N1 influenza A virus. *Obesity*. 2013;21(11):2377–2386. doi:10.1002/oby.20383
56. Honce R, Schultz-Cherry S. Impact of obesity on influenza a virus pathogenesis, immune response, and evolution. *Front Immunol*. 2019;10:1071. doi:10.3389/fimmu.2019.01071
57. O'Brien KB, Vogel P, Duan S, et al. Impaired wound healing predisposes obese mice to severe influenza virus infection. *J Infect Dis*. 2012;205(2):252–261. doi:10.1093/infdis/jir729
58. Sanjabi S, Zenewicz LA, Kamanaka M, Flavell RA. Anti-inflammatory and pro-inflammatory roles of TGF-beta, IL-10, and IL-22 in immunity and autoimmunity. *Curr Opin Pharmacol*. 2009;9(4):447–453. doi:10.1016/j.coph.2009.04.008
59. Muhl H, Pfeilschifter J. Anti-inflammatory properties of pro-inflammatory interferon-gamma. *Int Immunopharmacol*. 2003;3(9):1247–1255. doi:10.1016/S1567-5769(03)00131-0
60. Maier HE, Lopez R, Sanchez N, et al. Obesity increases the duration of influenza a virus shedding in adults. *J Infect Dis*. 2018;218(9):1378–1382. doi:10.1093/infdis/jiy370
61. Honce R, Karlsson EA, Wohlgenuth N, et al. Obesity-related microenvironment promotes emergence of virulent influenza virus strains. *mBio*. 2020;11(2). doi:10.1128/mBio.03341-19
62. Knoll M, Honce R, Meliopoulos V, Schultz-Cherry S, Ghedin E, Gresham D. Host obesity impacts genetic variation in influenza A viral populations. *bioRxiv*. 2023. doi:10.1101/2023.07.12.548715
63. Honce R, Jones J, Meliopoulos VA, et al. Efficacy of oseltamivir treatment in influenza virus-infected obese mice. *mBio*. 2023;14(4):e0088723. doi:10.1128/mbio.00887-23
64. Alsuwailam SI, Okmi EA, Alkhalidi EH, Almutairi KS, Alshamari WK. Determinants of flu vaccine uptake among the general population in Saudi Arabia: a study based on the health belief model. *Cureus*. 2023;15:7.
65. Szollosi GJ, Minh NC, Santoso CMA, Zsuga J, Nagy AC, Kardos L. An exploratory assessment of factors with which influenza vaccine uptake is associated in Hungarian adults 65 years old and older: findings from European health interview surveys. *Int J Environ Res Public Health*. 2022;19(12):7545. doi:10.3390/ijerph19127545
66. Karachaliou M, Damianaki I, Moudatsaki M, et al. Influenza vaccination coverage rates and determinants in Greek children until the age of ten (2008–2019), the rhea mother-child cohort. *Vaccines*. 2023;11(7):1241. doi:10.3390/vaccines11071241
67. Strouthou E, Karageorgos SA, Christaki E, Agouridis AP, Tsioutis C. Medical students' attitudes and perceptions of influenza and SARS-CoV-2 vaccination in Cyprus. *Germs*. 2022;12(2):180–194. doi:10.18683/germs.2022.1321
68. Wiggins KB, Smith MA, Schultz-Cherry S. The nature of immune responses to influenza vaccination in high-risk populations. *Viruses*. 2021;13(6):1109. doi:10.3390/v13061109
69. Mungmunpuntipantip R, Wiwanitkit V. Comment on "Medical students' attitudes and perceptions of influenza and SARS-CoV-2 vaccination in Cyprus". *Germs*. 2023;13(2):192–193. doi:10.18683/germs.2023.1385
70. Kim YH, Kim JK, Kim DJ, et al. Diet-induced obesity dramatically reduces the efficacy of a 2009 pandemic H1N1 vaccine in a mouse model. *J Infect Dis*. 2012;205(2):244–251. doi:10.1093/infdis/jir731
71. Park HL, Shim SH, Lee EY, et al. Obesity-induced chronic inflammation is associated with the reduced efficacy of influenza vaccine. *Hum Vaccin Immunother*. 2014;10(5):1181–1186. doi:10.4161/hv.28332
72. Frasca D, Romero M, Diaz A, Blomberg BB. Obesity accelerates age defects in B cells, and weight loss improves B cell function. *Immun Ageing*. 2023;20(1):35. doi:10.1186/s12979-023-00361-9
73. Neidich SD, Green WD, Rebeles J, et al. Increased risk of influenza among vaccinated adults who are obese. *Int J Obes*. 2017;41(9):1324–1330. doi:10.1038/ijo.2017.131
74. Esposito S, Giavoli C, Trombetta C, et al. Immunogenicity, safety and tolerability of inactivated trivalent influenza vaccine in overweight and obese children. *Vaccine*. 2016;34(1):56–60. doi:10.1016/j.vaccine.2015.11.019
75. Clarke M, Mathew SM, Giles LC, et al. A prospective study investigating the impact of obesity on the immune response to the quadrivalent influenza vaccine in children and adolescents. *Vaccines*. 2022;10(5):5. doi:10.3390/vaccines10050699

Diabetes, Metabolic Syndrome and Obesity

Dovepress

Publish your work in this journal

Diabetes, Metabolic Syndrome and Obesity is an international, peer-reviewed open-access journal committed to the rapid publication of the latest laboratory and clinical findings in the fields of diabetes, metabolic syndrome and obesity research. Original research, review, case reports, hypothesis formation, expert opinion and commentaries are all considered for publication. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit <http://www.dovepress.com/testimonials.php> to read real quotes from published authors.

Submit your manuscript here: <https://www.dovepress.com/diabetes-metabolic-syndrome-and-obesity-journal>